Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 1,174 results

Search Constraints

Start Over You searched for: Author "Stilgenbauer, Stephan" Remove constraint Author: "Stilgenbauer, Stephan" Language english Remove constraint Language: english
1,174 results on '"Stilgenbauer, Stephan"'

Search Results

2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

6. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

7. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

8. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

9. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

10. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

11. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

12. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

13. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

14. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis

16. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform

17. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

18. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

19. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

21. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

22. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

23. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

24. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

25. Molecular map of chronic lymphocytic leukemia and its impact on outcome

26. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

27. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

28. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

29. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia

30. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

32. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

33. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape

34. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

35. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

36. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

37. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

38. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

39. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.

41. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

42. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

43. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial

44. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

45. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

46. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas

47. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

49. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Catalog

Books, media, physical & digital resources